The study, conducted by the oncology department at Soroka Hospital in southern Israel, examined the contribution of the use of "Guardant360" non-invasive liquid biopsy to match accurate treatment for patients with metastases.
Guardant360 test detects DNA segments in the patient's blood, originated from the cancerous tumor or its metastasis.
After examining 116 advanced stage non-small-cell lung carcinoma cancer patients, the study concluded that 65 percent of the patients had a genetic modification that could be treated with drugs approved by the US Food and Drug Administration.
(This story has not been edited by Social News XYZ staff and is auto-generated from a syndicated feed.)
